<DOC>
	<DOCNO>NCT01373086</DOCNO>
	<brief_summary>This study ass efficacy safety LFF269 compare placebo treatment subject essential hypertension .</brief_summary>
	<brief_title>LFF269 Compared Placebo After Treatment Subjects With Essential Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Eplerenone</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<criteria>1 . Male female ( postmenopausal surgically sterile ) . 2 . Age 18 75 year inclusive . 3 . Subjects mildtomoderate uncomplicated essential hypertension , ( 2 combination ) without prior treatment . 4 . Subjects must weigh least 50 kg participate study , must body mass index ( BMI ) within range 18 36 kg/m2 . 1 . History evidence secondary form hypertension , 2 . History cardiovascular disease . Type 1 type 2 diabetes mellitus . 3 . Clinically significant valvular heart disease . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Hypertension ,</keyword>
	<keyword>mild hypertension ,</keyword>
	<keyword>moderate hypertension ,</keyword>
	<keyword>high blood pressure ,</keyword>
	<keyword>uncomplicated hypertension .</keyword>
</DOC>